Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study

A Banerjee, D A Lane, C Torp-Pedersen, G Y H Lip

    270 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study'. Together they form a unique fingerprint.

    Medicine & Life Sciences